Connor Clark & Lunn Investment Management Ltd. Buys 409,357 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Connor Clark & Lunn Investment Management Ltd. increased its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 88.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 871,527 shares of the company's stock after buying an additional 409,357 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 1.23% of Ventyx Biosciences worth $1,909,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Sio Capital Management LLC grew its holdings in Ventyx Biosciences by 153.2% during the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company's stock valued at $4,299,000 after purchasing an additional 1,193,024 shares during the last quarter. Vestal Point Capital LP grew its holdings in Ventyx Biosciences by 31.2% during the third quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock valued at $3,760,000 after purchasing an additional 410,000 shares during the last quarter. XTX Topco Ltd acquired a new position in Ventyx Biosciences during the third quarter valued at approximately $246,000. LMR Partners LLP acquired a new position in Ventyx Biosciences during the third quarter valued at approximately $218,000. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Ventyx Biosciences by 19.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 568,479 shares of the company's stock valued at $1,239,000 after purchasing an additional 92,753 shares during the last quarter. Institutional investors and hedge funds own 97.88% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "neutral" rating on shares of Ventyx Biosciences in a research report on Tuesday, January 14th.

Insider Buying and Selling

In other news, Director Sheila Gujrathi bought 130,000 shares of Ventyx Biosciences stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average cost of $2.31 per share, with a total value of $300,300.00. Following the completion of the transaction, the director now directly owns 130,000 shares in the company, valued at $300,300. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John Nuss sold 21,119 shares of the firm's stock in a transaction on Friday, December 27th. The stock was sold at an average price of $2.36, for a total value of $49,840.84. Following the completion of the transaction, the insider now directly owns 464,582 shares of the company's stock, valued at approximately $1,096,413.52. This trade represents a 4.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 18.18% of the stock is owned by company insiders.

Ventyx Biosciences Trading Down 0.8 %

VTYX stock traded down $0.01 during midday trading on Friday, hitting $1.32. The stock had a trading volume of 968,046 shares, compared to its average volume of 1,264,884. The firm has a market capitalization of $93.89 million, a price-to-earnings ratio of -0.56 and a beta of 0.58. Ventyx Biosciences, Inc. has a 52 week low of $1.28 and a 52 week high of $7.36. The stock has a 50-day simple moving average of $1.71 and a 200 day simple moving average of $2.08.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.13. On average, equities analysts forecast that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.